Publications with acknowledged Niche Science & Technology Contributions
Hardman et al. The future of clinical trials and drug development: 2050. Drugs Context
Eastwood et al. A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex.
Quing et al. Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control. J Allergy Clin Immunol
Hardman et al. The future of clinical trials and drug development: 2050. Drugs Context
Eastwood et al. A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex.
Quing et al. Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control. J Allergy Clin Immunol
Niche Science & Technology Publications
Hardman et al. The future of clinical trials and drug development: 2050. Drugs Context
Eastwood et al. A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex.
Quing et al. Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control. J Allergy Clin Immunol
Hardman et al. The future of clinical trials and drug development: 2050. Drugs Context
Eastwood et al. A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex.
Quing et al. Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control. J Allergy Clin Immunol
